BioCentury
ARTICLE | Clinical News

Bayer's ADC fails in mesothelioma trial

July 21, 2017 10:08 PM UTC

Bayer AG (Xetra:BAYN) said antibody-drug conjugate anetumab ravtansine (BAY 94-9343) missed the primary endpoint of progression-free survival (PFS) in a Phase II trial to treat malignant pleural mesothelioma (MPM) in a second-line setting. The study compared the ADC with vinorelbine in patients whose disease had progressed following chemotherapy.

Anetumab ravtansine consists of a human HuCAL IgG1 mAb targeting mesothelin conjugated to the maytansinoid tubulin inhibitor DM4. It uses HuCAL technology from MorphoSys AG (Xetra:MOR; Pink:MPSYY)...

BCIQ Company Profiles

Bayer AG

MorphoSys AG